LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Suletud

1.34 -4.29

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.33

Max

1.35

Põhinäitajad
By Trading Economics
Sissetulek	17M -26M
Töötajad	171
EBITDA	19M -23M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+97.78% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-21M 81M
Eelmine avamishind	5.63
Eelmine sulgemishind	1.34

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. märts 2026, 21:14 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: Central Bank Decisions -2-

15. märts 2026, 21:14 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

16. märts 2026, 00:00 UTC

Uudisväärsed sündmused

Hack on U.S. Medical Company Shows Reach of Iran's Cyber Capabilities -- WSJ

15. märts 2026, 23:45 UTC

Market Talk

Nikkei May Decline on Concerns About Prolonged Middle East Conflict -- Market Talk

15. märts 2026, 23:44 UTC

Market Talk

Uudisväärsed sündmused

Gold Falls as Rising Energy Prices Exacerbate Inflation Worries -- Market Talk

15. märts 2026, 23:35 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Rise on Supply Disruption Concerns -- Market Talk

15. märts 2026, 23:00 UTC

Omandamised, ülevõtmised, äriostud

Micron Completes Acquisition Of PSMC's Tongluo P5 Site In Taiwan >MU

15. märts 2026, 22:37 UTC

Market Talk

March Rate Hike Would Distance RBA From Government's May Budget -- Market Talk

15. märts 2026, 22:18 UTC

Market Talk

RBA's Likely Hike Motivated By Inflation, Not Middle East -- Market Talk

15. märts 2026, 22:14 UTC

Tulu

Genscript Biotech 2025 Adj Net $230.35M Vs. Adj Net $59.83M>1548.HK

15. märts 2026, 22:14 UTC

Tulu

Genscript Biotech: 2025 Loss Due to High Base Effect, One-off Unrealized Gains Seen Last Year >1548.HK

15. märts 2026, 22:14 UTC

Tulu

Genscript Biotech 2025 Rev $959.53M Vs. $594.49M >1548.HK

15. märts 2026, 22:14 UTC

Tulu

Genscript Biotech 2025 Loss $532.83M Vs. Net $2.96B >1548.HK

15. märts 2026, 22:14 UTC

Tulu

Genscript Biotech: 2025 Rev Supported by Substantial Increase in License Revenue>1548.HK

15. märts 2026, 22:00 UTC

Uudisväärsed sündmused

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

15. märts 2026, 22:00 UTC

Uudisväärsed sündmused

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

15. märts 2026, 03:00 UTC

Uudisväärsed sündmused

For Xi, Iran War Reinforces View of U.S. as Dangerous Superpower -- WSJ

14. märts 2026, 15:00 UTC

Uudisväärsed sündmused

Iran War Delivers Windfall to America's Oil Country -- WSJ

14. märts 2026, 02:03 UTC

Tulu

This Copper Stock Is Worth Mining for Profits -- Barrons.com

14. märts 2026, 01:32 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square IPO Is Back On -- Barrons.com

14. märts 2026, 00:29 UTC

Omandamised, ülevõtmised, äriostud

13D Filings -- Barrons.com

13. märts 2026, 22:27 UTC

Market Talk

Uudisväärsed sündmused

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

13. märts 2026, 22:13 UTC

Market Talk

Uudisväärsed sündmused

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

13. märts 2026, 22:04 UTC

Market Talk

Uudisväärsed sündmused

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

13. märts 2026, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

13. märts 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

13. märts 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

13. märts 2026, 20:02 UTC

Market Talk

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

13. märts 2026, 19:50 UTC

Market Talk

Uudisväärsed sündmused

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

13. märts 2026, 19:35 UTC

Uudisväärsed sündmused

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

97.78% tõus

12 kuu keskmine prognoos

Keskmine 2.67 USD 97.78%

Kõrge 3 USD

Madal 2 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Pliant Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.